UNDERSTANDING AND TARGETING RESISTANCE in Glioblastoma (UNITE Glioblastoma) is a unique research initiative funded within the frame of the program for Collaborative Research Centers (Sonderforschungsbereiche) of the German Research Foundation (Deutsche Forschungsgemeischaft). The initiative is coordinated by the University of Heidelberg and brings together physician-scientists and scientists from the Heidelberg University Hospital (UKHD), the University Hospital Mannheim (UMM), the German Cancer Research Center (DKFZ) and the Mannheim University of Applied Sciences (Hochschule Mannheim (HSMA)).
UNITE Glioblastoma is triggered by the strong vision that glioblastoma is treatable. To tackle this challenge, the research strategy is driven by innovation, strong collaboration and a focus on clinical implementation.
The UNITE research program focuses on unraveling mechanisms of intrinsic resistance (Focus A) and mechanisms of resistance conferred by the microenvironment (Focus B). Utilizing state-of the art technological innovation, novel high-throughput technologies, preclinical models, and analytical tools will be developed, applied, and shared as a resource within the initiative (Focus C). Integrated cores for tissue material, including a core set of jointly used patient-derived models, and integrative data analysis (Focus D) support work package leaders to efficiently use personal multi-dimensional-omic data for therapy guidance and precision medicine. For 100 selected tissue samples – the UNITE Core Collection – a uniform, integrated data matrix, consisting of multi-omics, imaging and clinical data, will be generated to understand initiation, progression and therapy resistance of glioblastomas at a molecular basis of patient-derived tissues. By drawing a multidimensional map of therapy resistance, UNITE aims to develop concepts to predict and monitor treatment response and failure, and ultimately, to invent novel (combination) therapies for glioblastoma patients.